The complex HLA-E-nonapeptide in Behçet disease.
Behçet disease
HLA-E
NK cells
classical HLA Class I molecules
gene association
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
10
2022
accepted:
04
07
2023
medline:
29
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
The knowledge of the aetiology of Behçet disease (BD), an immune-mediated vasculitis, is limited. HLA-B, mainly HLA-B51, and HLA-A molecules are associated with disease, but the ultimate cause of this association remains obscure. There is evidence that NK cells participate in the etiopathology of BD. NK cells have activator and inhibitor surface receptors, like the KIR and the NKG2 families. Classical HLA-class I molecules (A, B and C) are keys in the activity control of the NK because they are KIR ligands. Most NKG2 receptors bind HLA-E, which presents only nonapeptides derived from the signal peptide of other class-I molecules. This study investigates the contribution of the pair HLA-E and ligand, nonapeptide derived from the 3-11 sequence of the signal peptides of class I classical molecules, to the susceptibility to BD. We analyzed the frequency of the HLA-derivated nonapeptide forms in 466 BD patients and 444 controls and an HLA-E functional dimorphism in a subgroup of patients and controls. Results: In B51 negative patients, the frequency of VMAPRTLLL was lower (70.4% versus 80.0% in controls; P=0.006, Pc=0.04, OR=0.60, 95%CI 0.41-0.86), and the frequency of VMAPRTLVL was higher (81.6% versus 71.4% in controls; P=0.004, Pc=0.03, OR=1.78, 95%CI 1.20-2.63). In homozygosity, VMAPRTLLL is protective, and VMAPRTLVL confers risk. The heterozygous condition is neutral. There were no significant differences in the distribution of the HLA-E dimorphism. Our results explain the association of BD with diverse HLA-A molecules, reinforce the hypothesis of the involvement of the NK cells in the disease and do not suggest a significant contribution of the HLA-E polymorphism to disease susceptibility.
Identifiants
pubmed: 37638008
doi: 10.3389/fimmu.2023.1080047
pmc: PMC10449640
doi:
Substances chimiques
HLA-A Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080047Informations de copyright
Copyright © 2023 Castaño-Núñez, Montes-Cano, García-Lozano, Ortego-Centeno, García-Hernández, Espinosa, Graña-Gil, Sánchez-Bursón, Juliá, Solans, Blanco, Barnosi-Marín, Gómez de la Torre, Fanlo, Rodríguez-Carballeira, Rodríguez-Rodríguez, Camps, Castañeda, Alegre-Sancho, Martín and González-Escribano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Exp Immunol. 2015 Dec;182(3):270-7
pubmed: 26307125
Nat Genet. 2013 Mar;45(3):319-24
pubmed: 23396137
J Exp Med. 2000 Sep 4;192(5):613-24
pubmed: 10974028
J Autoimmun. 2009 May-Jun;32(3-4):178-88
pubmed: 19324519
Eur J Immunol. 1997 May;27(5):1164-9
pubmed: 9174606
Immunol Invest. 2019 Feb;48(2):121-129
pubmed: 30260727
Arthritis Res Ther. 2011 Mar 24;13(2):R49
pubmed: 21429233
EMBO J. 1999 Aug 2;18(15):4250-60
pubmed: 10428963
PLoS One. 2016 Aug 22;11(8):e0161305
pubmed: 27548383
Int J Mol Sci. 2019 Nov 04;20(21):
pubmed: 31690066
J Immunol. 2008 Nov 1;181(9):6293-300
pubmed: 18941220
Immunol Res. 2006;35(3):263-78
pubmed: 17172651
HLA. 2017 Mar;89(3):143-149
pubmed: 28127896
Immunol Res. 2004;30(1):29-34
pubmed: 15258309
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8867-72
pubmed: 24821759
J Immunol. 2003 Aug 1;171(3):1369-75
pubmed: 12874227
Arthritis Res Ther. 2009;11(6):R171
pubmed: 19912639
Mol Cell. 1998 Mar;1(4):531-41
pubmed: 9660937
Immunol Rev. 2015 Sep;267(1):148-66
pubmed: 26284476
Arthritis Rheum. 2009 Oct 15;61(10):1287-96
pubmed: 19790126
J Mol Biol. 2008 Apr 11;377(5):1297-303
pubmed: 18339401
RMD Open. 2018 Jun 28;4(1):e000677
pubmed: 30018800
Nat Commun. 2017 Jun 26;8:15924
pubmed: 28649982
Arthritis Res Ther. 2013 Oct 04;15(5):R145
pubmed: 24286189
Front Immunol. 2021 Feb 25;12:622306
pubmed: 33717125
Immunity. 2007 Dec;27(6):900-11
pubmed: 18083576
Tissue Antigens. 2007 Feb;69(2):139-44
pubmed: 17257316
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8706-7
pubmed: 24876276
J Immunol. 2005 Mar 1;174(5):2878-84
pubmed: 15728498
Clin Exp Immunol. 2019 May;196(2):167-177
pubmed: 30968409
J Immunol. 1998 Jan 1;160(1):171-9
pubmed: 9551969
J Biol Chem. 2003 Feb 14;278(7):5082-90
pubmed: 12411439
Sci Immunol. 2016 Sep;1(3):
pubmed: 27868107
Sci Rep. 2019 Mar 14;9(1):4426
pubmed: 30872678
J Autoimmun. 2015 Nov;64:137-48
pubmed: 26347074
J Immunol. 1998 May 15;160(10):4951-60
pubmed: 9590243
Exp Dermatol. 2013 Oct;22(10):679-81
pubmed: 24079744
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380